Indian pharma industry growth is driven by Supply Side Drivers, demand-side drivers, and government policy support.
References:
https://www.ibef.org/industry/pharmaceutical-india.aspx
This PPT contains complete analysis of Pharmaceutical Industry including worldwide and nationwide picture, leading organizations, SWOT analysis, Government policies and regulations, challenges and solutions.
This PPT contains complete analysis of Pharmaceutical Industry including worldwide and nationwide picture, leading organizations, SWOT analysis, Government policies and regulations, challenges and solutions.
“SWOT ANALYSIS OF NEW PHARMACEUTICAL COMPANY” Dharmik Bhatt
Main Objective
To find the Strength, weakness, Opportunities and threat of the company and all new pharmaceutical companies.
To find out the perception and expectation of doctors and retailers towards the new pharmaceutical company.
Sub Objectives
To find out the big player of the market (Tough Competitor).
To find the way for new pharmaceutical company from tough competition.
To create strategy for company with the help of research detail.
To analyze Vadodara market for company.
To create good communication bridge between new company to doctors and retailers, that full feel all require expectation of both.
This presentation is brief introduction of Pharma Market and work pattern of MNCs (GSK is taken as example).This presentation was given by Faheem Siddiqui in Entrepreneur Conference at MBBS campus-Dadu of Sindh University on 09th October-13
India is the largest provider of generic drugs globally. Indian pharmaceutical sector industry supplies over 50 per cent of global demand for various vaccines, 40 per cent of generic demand in the US and 25 per cent of all medications in the UK.
India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers who have the potential to steer the industry ahead to an even higher level. Presently over 80 per cent of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) is supplied by Indian pharmaceutical firms.
Pharmaceuticals Industry Analysis with analysis of Top notch Companies in pharmaceuticals viz. Sun pharma, Lupin, Dr. Reddy's Laboratory, Cipla, Aurobindo Pharma to identify opportunity to invest in equity share of these companies.
The pharmacy retail market is valued at INR 216 bn in 2009 and estimated to reach INR 432 bn in 2011. The market is fragmented and dominated by the unorganized sector.
The report provides a snapshot of the pharmacy retail market. Market overview gives a quick picture of the market with estimated market size, growth rate and revenue split between the organized and unorganized sector. An analysis of drivers reveals that growth in pharmaceuticals sector, increase in healthcare spending, changing disease profile, consumer attitudes, attractive margins and growth in OTC segment is driving growth in this sector. The key challenges identified include fragmented nature of Industry, lengthy supply chain, counterfeit drugs and FDI Regulations.
The report identifies the current market trends including loyalty schemes, value added services, tie-ups with retail firms, rural expansion, entry of Government in pharmacy retailing, entry of private labels, organized retailers starting pharmacy chains. The competitive landscape profiles the major players in this sector including the business description, number of stores and expansion plans for each player. The report also provides details of the key developments in this sector.
Market research for Indian Pharmaceutical Market switching over from prescribed to OTC products. Scope of Indian Pharmaceutical OTC market, opportunities and challenges.
Sun pharma- A complete company review, analysis of crisis and realistic recom...TilikaChawda
Sun pharma has been the most talked about Indian pharma company for being in the news several times for its unresolved issues with the US FDA regarding the Halol and Mohali plant.
This presentation has analysed the situation and it suggests various solutions for the same.
Introduction to indian pharma industriespharmacampus
Introduction to Indian Pharma Industries: this highlights leading pharma producers, details of exports of medicines, growth statistics, and high potential generic market.
Advantages of Pharma in India, Market Share and Economic Drivers, Structure of Pharma Sector, Evolution of Pharma, Revenue %, Market Share, Porter 5 Force Model, BCG Matrix, Government Policies, Opportunities.
“SWOT ANALYSIS OF NEW PHARMACEUTICAL COMPANY” Dharmik Bhatt
Main Objective
To find the Strength, weakness, Opportunities and threat of the company and all new pharmaceutical companies.
To find out the perception and expectation of doctors and retailers towards the new pharmaceutical company.
Sub Objectives
To find out the big player of the market (Tough Competitor).
To find the way for new pharmaceutical company from tough competition.
To create strategy for company with the help of research detail.
To analyze Vadodara market for company.
To create good communication bridge between new company to doctors and retailers, that full feel all require expectation of both.
This presentation is brief introduction of Pharma Market and work pattern of MNCs (GSK is taken as example).This presentation was given by Faheem Siddiqui in Entrepreneur Conference at MBBS campus-Dadu of Sindh University on 09th October-13
India is the largest provider of generic drugs globally. Indian pharmaceutical sector industry supplies over 50 per cent of global demand for various vaccines, 40 per cent of generic demand in the US and 25 per cent of all medications in the UK.
India enjoys an important position in the global pharmaceuticals sector. The country also has a large pool of scientists and engineers who have the potential to steer the industry ahead to an even higher level. Presently over 80 per cent of the antiretroviral drugs used globally to combat AIDS (Acquired Immune Deficiency Syndrome) is supplied by Indian pharmaceutical firms.
Pharmaceuticals Industry Analysis with analysis of Top notch Companies in pharmaceuticals viz. Sun pharma, Lupin, Dr. Reddy's Laboratory, Cipla, Aurobindo Pharma to identify opportunity to invest in equity share of these companies.
The pharmacy retail market is valued at INR 216 bn in 2009 and estimated to reach INR 432 bn in 2011. The market is fragmented and dominated by the unorganized sector.
The report provides a snapshot of the pharmacy retail market. Market overview gives a quick picture of the market with estimated market size, growth rate and revenue split between the organized and unorganized sector. An analysis of drivers reveals that growth in pharmaceuticals sector, increase in healthcare spending, changing disease profile, consumer attitudes, attractive margins and growth in OTC segment is driving growth in this sector. The key challenges identified include fragmented nature of Industry, lengthy supply chain, counterfeit drugs and FDI Regulations.
The report identifies the current market trends including loyalty schemes, value added services, tie-ups with retail firms, rural expansion, entry of Government in pharmacy retailing, entry of private labels, organized retailers starting pharmacy chains. The competitive landscape profiles the major players in this sector including the business description, number of stores and expansion plans for each player. The report also provides details of the key developments in this sector.
Market research for Indian Pharmaceutical Market switching over from prescribed to OTC products. Scope of Indian Pharmaceutical OTC market, opportunities and challenges.
Sun pharma- A complete company review, analysis of crisis and realistic recom...TilikaChawda
Sun pharma has been the most talked about Indian pharma company for being in the news several times for its unresolved issues with the US FDA regarding the Halol and Mohali plant.
This presentation has analysed the situation and it suggests various solutions for the same.
Introduction to indian pharma industriespharmacampus
Introduction to Indian Pharma Industries: this highlights leading pharma producers, details of exports of medicines, growth statistics, and high potential generic market.
Advantages of Pharma in India, Market Share and Economic Drivers, Structure of Pharma Sector, Evolution of Pharma, Revenue %, Market Share, Porter 5 Force Model, BCG Matrix, Government Policies, Opportunities.
Make In India – Healthcare Reforms, Insurance, Innovations, Investments & Inf...Indian Affairs
7th Annual Pharmaceutical Leadership Summit & Pharmaleaders Business Leadership Awards 2014
Friday, 26th December, Hotel Sahara Star, Mumbai, India
Make In India – Healthcare Reforms
Insurance,Innovations,Investments & Infrastructure
“Empowering India’s Developing Healthcare System”
Investing the Healthcare Solutions of Tomorrow in difficult Times
Make In India – Healthcare Reforms, Insurance, Innovations, Investmentspharmaleaders
7th Annual Pharmaceutical Leadership Summit & Pharmaleaders Business Leadership Awards 2014
Friday, 26th December, Hotel Sahara Star, Mumbai, India
Make In India – Healthcare Reforms
Insurance,Innovations,Investments & Infrastructure
“Empowering India’s Developing Healthcare System”
Investing the Healthcare Solutions of Tomorrow in difficult Times Theme Address : Make In India – Healthcare Reforms, Insurance, Innovations, Investments & Infrastructure.
Mr. Daara Patel, Secretary General, IDMA ( Indian Drug Manufacturers Association)
Indian pharmaceutical history began from Gupta period which was existed from approximately 320 to 550 CE where people were dependent only on indigenous form of medicine before British rule.
In India Allopathic medication was started in British rule, but production of such medicines was not in the country.
In 1901 Acharya P C Ray started first Indian Pharmaceutical Industry, Bangal Chemical in Calcutta.
The government started to encourage the growth of drug manufacturing by Indian companies in the early 1960s, and with the Patents Act in 1970.
However, economic Liberalization in 90s enabled the industry to become what it is today.
Status of pharmaceutical industry in indiaShadab Khan
Status of Pharmaceutical Industry in India
-History
-Evolution
-Current Scenario
-Market Share
-Government Initiatives
-Top 10 Pharmaceutical Industry
-R&D Spendings
-Challenges
-Road Ahead
National and international status of pharma indus.Priyesh Pandya
The pharmaceutical industry is responsible for the development, production and marketing of medications.
The industries is expected to register growth led by aging population, changing lifestyles, hectic daily activities, unhealthy eating, increasing incidence of chronic diseases across the global population providing growth opportunities for the industry players.
Prescription drug sales expected to reach $1.18trn in 2024.
I have to try to share some knowledge about the Indian health care sector. I have put some data to get more and more knowledge which can easily understand.
Indian Pharmaceutical Export Market - Top Export Destinations for Indian Phar...Irish Pereira
By Mr. Irish Pereira. The report present snapshot of Indian Pharmaceutical industry in both domestic as well as export market. It is collation of facts pertaining to Indian pharma exports and explore key emerging trends pertaining to pharma export market. It describes key players of Indian pharma market and their export orientation as in their target export destinations, their focus therapies etc.
Fact sheet:
1) Indian Pharma Market size 2015
2) Indian pharmaceutical market segments by value
3)Patented (Innovator) Vs Generics Scenario
4)Growth drivers of Indian pharmaceutical industry
5) Indian Pharmaceutical sector – SWOT Analysis
6)PHARMEXCIL – Facilitating agency for Indian Pharma Exports
7) Indian Pharmaceutical Exports (USD bn)
8)Formulations share in Total Pharma Exports (2014-15)
9) Top 25 destination countries of India’s pharmaceutical exports during 2013-14 (INR mn)
10) Major Indian Pharma Companies (By Revenue-USD mn)
11) Pharma players and their export destinations
Sun Pharma,Dr. Reddy’s Lab,
CIPLA, Lupin, Aurobindo, Cadila Healthcare, Torrent Pharma, Wockhardt,
12) Emerging trends in Indian Pharma Market
The basic metabolic defect in type 2 DM is either a delayed insulin secretion relative to glucose load (impaired insulin secretion), or the peripheral tissues are unable to respond to insulin (insulin resistance).
Diagnostic tests for GI disorders- include physical evaluation, blood tests, imaging techniques. Learn the methods of diagnosis in detail, for gastrointestinal disorders.
Anatomy & Physiology of GIT: It covers Organs of the Digestive system, Structure of the Alimentary canal, Mouth, Salivary glands, Pharynx, Oesophagus, Stomach, Small intestine, Large intestine, Rectum & Anal canal, Pancreas, Liver, Biliary tract
Rheumatoid arthritis- diagnosis and treatment pharmacampus
Rheumatoid arthritis is a chronic inflammatory disorder that can affect more than just your joints. The condition can damage various body systems, including the skin, eyes, lungs, heart, and blood vessels.
ACE inhibitors block the angiotensin-converting enzyme found throughout vascular tissue that converts angiotensin I to angiotensin II. Let us know how do ACE Inhibitors work?
Bioavailability studies are designed to determine either an absolute BA or relative BA.
They can be used to compare different routes of administration.
Methods for Measurement of bioavailability pharmacampus
Which are the Methods for Measurement of bioavailability?- Pharmacokinetic method- Plasma level time studies, Urinary excretion studies.
Pharmacodynamic method: Acute pharmacologic response, Therapeutic response.
Which are the Factors affecting bioavailability?pharmacampus
Factors affecting bioavailability: The dosage form factors, food effects, cellular structure, pH environment, GI transit time, physiology-related factors, etc.
What are the applications of Biostatistics in Pharmacy?pharmacampus
Biostatistics broadly deals with statistical applications in the context of biological problems, including medicine, pharmacy, and public health. Government organizations, research institutes and industry have been extensively using statistics and biostatistics
Bio-equivalence study of drugs: Let us know the Biopharmaceutical Classification System, why do we require a Bioequivalence study, and regulatory requirements.
Introduction to Bio-availability study pharmacampus
Bioavailability studies are done in clinical, academic, and regulatory interest. Objectives could be developing a new drug entity, Determination of the influence of Excipients, Patient-related factors.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stockrebeccabio
Factory Supply Best Quality Pmk Oil CAS 28578–16–7 PMK Powder in Stock
Telegram: bmksupplier
signal: +85264872720
threema: TUD4A6YC
You can contact me on Telegram or Threema
Communicate promptly and reply
Free of customs clearance, Double Clearance 100% pass delivery to USA, Canada, Spain, Germany, Netherland, Poland, Italy, Sweden, UK, Czech Republic, Australia, Mexico, Russia, Ukraine, Kazakhstan.Door to door service
Hot Selling Organic intermediates
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
2. Growth drivers-
Supply Side Drivers
PharmaCampus- All Rights reserved
• Cost advantage.
• Skilled manpower.
• India a major manufacturing hub for
generics.
• India accounts for 22 percent of overall
USFDA approved plants.
• Increase penetration of chemists.
3. Growth drivers-
Demand Side Drivers
• Increasing fatal diseases.
• Accessibility of drugs to greatly improve.
• Increasing penetration of health insurance.
• Growing number of stress-related diseases.
• Better diagnostic facilities.
PharmaCampus- All Rights reserved
4. Growth drivers-
Policy Support
PharmaCampus-
All
Rights
reserved
• National Health Policy
2015, which focuses on
increasing public
expenditure on
healthcare segment.
• Reduction in approval
for new facilities.
• Plans to set up new
pharmaceutical
education and research
institutes.
5. Growth Drivers
PharmaCampus- All Rights reserved
• Cost advantage.
• Skilled manpower.
• India a major manufacturing hub for generics.
• India accounts for 22 percent of overall USFDA
approved plants.
• Increase penetration of chemists.
Supply Side Drivers
• National Health Policy 2015, which focuses on
increasing public expenditure on healthcare segment.
• Reduction in approval for new facilities.
• Plans to set up new pharmaceutical education and
research institutes.
Demand Side Drivers
• Increasing fatal diseases.
• Accessibility of drugs to greatly improve.
• Increasing penetration of health insurance.
• Growing number of stress-related diseases.
• Better diagnostic facilities.
Policy Support
7. Launch of Patented
Drugs
• Following the introduction of product
patents, several multinational companies are
expected to launch patented drugs in India-
• Growth in the number of lifestyle diseases
in India could boost the sale of drugs in this
segment.
• High Court allowing to export patent drugs,
to foreign players in the Indian market.
PharmaCampus- All Rights reserved
9. • Pharma companies have increased
spending to tap rural markets and develop
better medical infrastructure.
• Hospitals’ market size is expected to
increase by US$ 200 billion by 2024.
• Medical devices industry in India has
been growing 17 per cent annually.
PharmaCampus- All Rights reserved
Medical
Infrastructure
11. Scope in Generics
Market
• India’s generic drugs account for 20
per cent of global exports in terms of
volume, making it the largest provider
of generic medicines globally.
• The generics drug market accounts
for around 70 per cent of the India
pharmaceutical industry and it is
expected to reach US$ 27.9 billion by
2020
PharmaCampus- All Rights reserved
13. Over-The-Counter
(OTC) Drugs
• India’s OTC drugs market is
estimated to have grown at a
CAGR of 16.3 per cent to US$
6.6 billion over.
• 2008–16 and is further expected
to grow on the account of
increased penetration of
chemists, especially in rural
regions.
• Indian OTC market is expected
to grow at a CAGR of 9 per cent
from 2016-26 to cross Rs 44,115
crore (US$ 6.81 billion).
PharmaCampus- All Rights reserved
15. Patent Expiry
• About 120 drugs are expected to go
off-patent over the next 10 years.
• The estimated worldwide revenue of
patent expiry is US$ 80 to 250 billion
PharmaCampus- All Rights reserved
16. Demand
Drivers
Accessibility
• Over US$ 200 billion to be spent on medical next
decade.
• New business models expected to penetrate
tier-2 and 3 boosting the OTC market.
• Over 160,000 hospital beds expected to be
added each year in the next decade.
Acceptability
• Rising levels of education to increase
acceptability of infrastructure in the
pharmaceuticals.
• Patients to show greater propensity to self-
medicate, cities.
• Acceptance of biologics and preventive
medicines to rise.
Affordability Epidemiological factors
• Rising income could drive 73 million households
to the increase over 20 per cent in middle class
over the next 10 years.
• Over 650 million people expected to be covered
by changes to boost demand health insurance
by 2020.
• Patient pool expected to the next 10 years,
mainly due to rise in population.
• New diseases and lifestyle.
• Increasing prevalence of lifestyle diseases
PharmaCampus- All Rights reserved
17. Demand drivers-
accessibility
• Over US$ 200 billion to be spent on
medical next decade.
• New business models expected to
penetrate tier-2 and 3 boosting the
OTC market.
• Over 160,000 hospital beds expected
to be added each year in the next
decade.
PharmaCampus- All Rights reserved
18. Demand drivers-
acceptability
• Rising levels of education to
increase acceptability of
infrastructure in the
pharmaceuticals.
• Patients to show greater
propensity to self-medicate,
cities.
• Acceptance of biologics and
preventive medicines to rise.
PharmaCampus- All Rights reserved
19. Demand drivers-
Epidemiological factors
• Patient pool expected to the next 10
years, mainly due to rise in population.
• New diseases and lifestyle.
• Increasing prevalence of lifestyle
diseases
PharmaCampus- All Rights reserved
20. Demand drivers-
Affordability
• Rising income could drive 73
million households to the
increase over 20 per cent in
middle class over the next 10
years.
• Over 650 million people
expected to be covered by
changes to boost demand health
insurance by 2020.
PharmaCampus- All Rights reserved
21. 9.28
11.05
12.03
13.14
14.95
19.89
23.38
11.66
0
5
10
15
20
25
FY 12 FY 13 FY 14 FY 15 FY 16 FY 17 FY 18 FY 19
Gross Directs Premium of Non-Life insurers (US$
billion)
Health
Others
Break-up of non-life insurance market in India
(FY18)
Increasing penetration of non-life insurance- will drive the expansion of healthcare services and
pharmaceutical market.
Gross direct premium from health insurance- reached Rs 378.97 billion (US$ 5.88 billion) in FY18 and
contributed 25.2 per cent to the gross direct premiums of non-life insurance companies in India.
In FY19 (up to November 2018), health insurance- premiums have increased 19.3 per cent year-on-year to
Rs 278.96 billion (US$ 3.87 billion).
PharmaCampus- All Rights reserved
